4:47 PM
 | 
Jun 03, 2014
 |  BC Extra  |  Company News

Prosensa planning NDA for drisapersen this year

Prosensa Holding N.V. (NASDAQ:RNA) said it plans to submit an NDA to FDA this year seeking accelerated approval of drisapersen ( PRO051) to treat Duchenne muscular dystrophy (DMD). The compound -- an antisense oligoribonucleotide that induces...

Read the full 170 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >